We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Lonza and Benitec Enter Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lonza and Benitec Enter Agreement"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Lonza Houston, Inc. and Benitec Biopharma have announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec’s ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.

This relationship will leverage Lonza’s expertise to facilitate the development of a cost-effective, scalable and robust suspension culture-based manufacturing platform, which is anticipated to enable the production of sufficient material to meet the potential demand for treating diseases that affect millions of people such as hepatitis C.

Benitec’s Vice-President of Manufacturing, Dr. Claudia Kloth, said, “As our lead ddRNAi-based hepatitis C therapy TT-034 continues to advance in clinical studies, Lonza is an ideal partner for us to optimize our large-scale production process based on its solid expertise and track record in process development and production of AAV-based gene therapeutics.”

Andreas Weiler, PhD, Head of Emerging Technologies for Lonza’s Pharma&Biotech segment, said, “This agreement with Benitec continues the development of our robust and large-scale AAV platform for the production of AAV-based viral gene therapies. Lonza will utilize our cGMP manufacturing knowledge and world-class quality systems to help Benitec develop these promising novel therapeutics for patients.”